Home / Companies / Hubei Enoray Biopharmaceutical Co., Ltd.

Hubei Enoray Biopharmaceutical Co., Ltd. FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

Hubei Enoray Biopharmaceutical Co., Ltd. has 0 FDA recalls, 2 inspections, 0 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "Hubei Enoray Biopharmaceutical Co., Ltd." is on file.

What these totals cover: FDA records filed under the name "Hubei Enoray Biopharmaceutical Co., Ltd." and its spelling variant "Hubei Enoray Biopharmaceutical Co".

Latest inspection: Mar 13, 2025 · NAI

Summary

Record counts and when each FDA source was last refreshed
Records	Count	Last refreshed	Source as of	Status
Recalls	0	Nov 8, 2026	File dated Nov 3, 2026	Current
510(k) clearances	0	Nov 8, 2026	File dated Nov 2, 2026	Current
Inspections	2	Nov 14, 2026	Newest record Nov 5, 2026	Current
Compliance actions	0	Nov 2, 2026	Newest record Oct 29, 2026	Current

FDA record by year

Hubei Enoray Biopharmaceutical Co., Ltd.'s FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

Year	Inspections	OAI	Warning letters	Recall records	Class I
2026	0	0	0	0	0
2025	1	0	0	0	0
2024	0	0	0	0	0
2023	0	0	0	0	0
2022	0	0	0	0	0
2021	0	0	0	0	0
2020	0	0	0	0	0
2019	0	0	0	0	0
2018	0	0	0	0	0
2017	1	0	0	0	0

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing Hubei Enoray Biopharmaceutical Co., Ltd. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Hubei Enoray Biopharmaceutical Co., Ltd. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Recent FDA inspections

2 inspections from Jul 27, 2017 to Mar 13, 2025.

Date	Site	Product	Classification	FEI
Mar 13, 2025	Huanggang, China	Drugs	No Action Indicated (NAI)	3010165284
Jul 27, 2017	Huanggang, China	Drugs	No Action Indicated (NAI)	3010165284

NAI: No objectionable conditions or practices were found during the inspection.
VAI: Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI: Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

FDA-inspected facilities

1 inspected site, newest inspection first.

Facility	Location	Inspections	Latest
FEI 3010165284	Huanggang, China	2	Mar 13, 2025

Hubei Enoray Biopharmaceutical Co., Ltd. and the FDA: common questions

Has Hubei Enoray Biopharmaceutical Co., Ltd. received an FDA warning letter?

No FDA warning letter addressed to the name "Hubei Enoray Biopharmaceutical Co., Ltd." is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.

Has Hubei Enoray Biopharmaceutical Co., Ltd. received an FDA Form 483?

FDA has not published a Form 483 for "Hubei Enoray Biopharmaceutical Co., Ltd." in its reading room. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect Hubei Enoray Biopharmaceutical Co., Ltd.?

The most recent FDA inspection on file ended Mar 13, 2025 at Huanggang, China and was classified NAI. FDA has 2 inspections of Hubei Enoray Biopharmaceutical Co., Ltd. on file.

Need more than this page shows? Ask about Hubei Enoray Biopharmaceutical Co., Ltd. in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.